Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2009
Business Overview: The company develops, manufactures, and markets oral fluid diagnostic products (including the OraQuick ADVANCE HIV test) and cryosurgical devices. A significant operational shift occurred on January 1, 2009, when the company terminated its distribution agreement with Abbott Laboratories and began selling the OraQuick ADVANCE test directly to U.S. hospitals.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenues | $17,256,451 | $18,088,819 |
| Gross Profit | $10,972,072 | $10,642,968 |
| Gross Margin | 64% | 59% |
| Operating Loss | $(1,860,242) | $(3,011,433) |
| Net Income (Loss) | $(1,617,961) | $2,001,737 |
| Diluted EPS | $(0.04) | $0.04 |
| Cash & Equivalents (End of Period) | $52,390,160 | $12,516,849 |
| Short-term Investments | $26,229,592 | $42,957,467 |
| Total Debt (Current + Long-term) | $8,719,971 | Not explicitly totaled in text |
| Working Capital | $90,116,055 | Not explicitly totaled in text |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 5% to $17.3 million. This was driven by a 36% drop in cryosurgical sales and an 18% decline in substance abuse testing, partially offset by a 10% increase in infectious disease testing.
- Profitability Shift: The company reported a net loss of $1.6 million compared to net income of $2.0 million in Q1 2008. The prior year's income included a one-time $4.9 million settlement payment from Schering-Plough recorded as "Other Income," which did not recur in 2009.
- Margin Expansion: Gross margin improved to 64% from 59%, attributed to reduced scrap/spoilage and higher margins from the new direct sales model for hospital customers.
- Expense Management: R&D expenses decreased 27% due to reduced clinical trial spending. However, General and Administrative expenses increased 16% due to legal costs associated with pending patent litigation.
- Cash Flow: Net cash used in operating activities improved to $2.7 million (from $3.7 million used in 2008), aided by the collection of a large international receivable. Investing activities provided $16.2 million in cash due to net redemptions of short-term investments.
Guidance, Outlook, and Risks
- Direct Sales Strategy: Management expects sales and marketing expenses to increase later in 2009 to support the direct sales model for the U.S. hospital market. Clinical trial expenses are also expected to rise.
- Economic Sensitivity: The company notes that the substance abuse testing market is heavily impacted by U.S. unemployment rates; growth is not expected until employment conditions recover.
- Product Cannibalization: Management observes that sales of the OraQuick ADVANCE rapid test are negatively impacting sales of the OraSure collection device as customers shift to rapid testing.
- Legal Contingency: The company is defending against a patent infringement lawsuit filed by Inverness Medical Innovations and Church & Dwight regarding the OraQuick ADVANCE test. A Markman hearing is scheduled for August 12, 2009. The company believes the patent is invalid but cannot determine the financial impact at this time.
- Liquidity: The company maintains a $14 million credit facility with Comerica Bank. Management believes current cash, investments, and available borrowings are sufficient to fund operations through the remainder of 2009.
Investor Verification Checklist
- Direct Sales Transition: Verify the sustainability of the 41% revenue increase in the U.S. hospital market following the Abbott termination.
- Patent Litigation: Monitor the outcome of the Inverness Medical/Church & Dwight lawsuit, specifically the August 2009 Markman hearing, for potential injunctions or damages.
- Cryosurgical Recovery: Assess the performance of the new "Freeze 'n Clear Skin Clinic" brand and the resumption of sales to distributor Genomma Labs in Q2 2009.
- Substance Abuse Market: Correlate future revenue projections with U.S. employment data, as the Intercept product line is directly tied to pre-employment screening.
- Inventory Levels: Review inventory turnover given the $9.9 million balance and the noted decline in international OTC cryosurgical sales.